ArticleThe Journal of general virology2021
The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
Article in The Journal of general virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease.Neurotoxicity research · 2022Pooled it
- Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.International journal of molecular sciences · 2021Pooled it
- Severe acute pancreatitis and toxic hepatitis after solitary dietary supplement ingestion: A case report.Medicine · 2026Article
- Pyrogallol B-ring enhances catechin binding to the SARS-CoV-2 spike receptor-binding domain to inhibit interaction with ACE2.Scientific reports · 2026Article
- Current State of Knowledge of the Anticancer Properties of Polyphenolic Compounds from Garlic (Molecules (Basel, Switzerland) · 2026Review
- Sumac Polyphenols as Pan-Herpesvirus Inhibitors.International journal of molecular sciences · 2025Article
- Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study andCurrent pharmaceutical design · 2025Review
- Epigallocatechin-3-gallate: a multi-target bioactive molecule derived from green tea against Oropouche virus-a computational approach to host-pathogen network modulation.Frontiers in chemistry · 2025Article
- Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.Inflammopharmacology · 2024Review
- Possible Combinatorial Utilization of Phytochemicals and Extracellular Vesicles for Wound Healing and Regeneration.International journal of molecular sciences · 2024Review
- In vitro study on efficacy of SKF7BMC complementary medicine and therapies · 2024Article
- Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.Journal of medicinal chemistry · 2024Article
- Bile acids and coronavirus disease 2019.Acta pharmaceutica Sinica. B · 2024Review
- Development of SARS-CoV-2 entry antivirals.Cell insight · 2024Review
- Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets.Pharmaceutical biology · 2023Review
- Antiviral Natural Products, Their Mechanisms of Action and Potential Applications as Sanitizers and Disinfectants.Food and environmental virology · 2023Review
- Colloidal aggregation confounds cell-based Covid-19 antiviral screens.bioRxiv : the preprint server for biology · 2023Article
- Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID.International journal of molecular sciences · 2023Article
- Effects of tea, catechins and catechin derivatives on Omicron subvariants of SARS-CoV-2.Scientific reports · 2023Article
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and more than a million deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. No treatment exists. Epigallocatechin-3-gallate (EGCG), the major component of green tea, has several beneficial properties, including antiviral activities. Therefore, we examined whether EGCG has antiviral activity against SARS-CoV-2. EGCG blocked not only the entry of SARS-CoV-2, but also MERS- and SARS-CoV pseudotyped lentiviral vectors and inhibited virus infections
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.